Studies in hepatic biopsy samples also revealed that MASLD patients were featured by the markedly downregulated UBC9 expression as compared to their counterparts, which was coupled with a markedly elevated p16 expression and a global reduction of SUMOylated proteins (Figure 1E,F). The gene discussed is CDKN2A; the disease is metabolic dysfunction-associated steatotic liver disease.